Q1 FY27 Results: Balurghat Technologies posts Rs 31 lakh profit vs loss last year

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-10.3%Reaction day

₹13.83

prior close

₹14.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-10.4% vs market

Transport Services peers, median of 62sector · industry level-0.2%-10.1% vs sector

On the reaction day the stock moved 10.4 pts less than Nifty Microcap 250 and 10.1 pts less than its Transport Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-7.1

10m

-10.6

15m

-7.1

30m

-7.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-10.3+0.1-10.4-0.2-10.1

Next day

-11.1+0.2-11.3+0.0-11.1

-11.5+0.6-12.1-0.8-10.7

-12.7-0.0-12.7-1.2-11.5

-12.5+0.5-13.0-1.0-11.5

-9.6+0.8-10.4-0.8-8.8

-9.6+0.6-10.2-1.5-8.1

15d

-7.0+1.3-8.3+0.0-7.0

-13.7-1.4-12.3-4.3-9.4

-7.7-0.6-7.1-4.9-2.7

—————

UpDownMarket · Nifty Microcap 250Sector · Transport Services peers, median of 62Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 (ended June 2026) unaudited results. Net sales rose to Rs 30.07 crore from Rs 27.92 crore YoY, up about 8 percent. Company swung to a net profit of Rs 31.22 lakh versus a Rs 66.83 lakh loss in Q1 FY26. EPS stood at Rs 0.18. Auditor issued an unqualified review report. Filing also discloses pending litigations, including a Rs 57.84 crore IDBI Bank corporate guarantee matter.

Likely market impact

Turnaround to profit signals improvement, but large pending litigations like the Rs 57.84 crore IDBI matter remain a key concern.